Urgent

Post-transfusion purpura (PTP)

Thrombocytopenia · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Sudden severe thrombocytopenia 5-12 days after a blood transfusion, typically in a previously alloimmunised (parous) woman with anti-HPA-1a antibodies. Self-limiting but can cause life-threatening bleeding; the patient destroys their OWN platelets.

Red flags

  • Intracranial or other major bleeding
  • Platelets <10

Assessment

Differential diagnosis

  • ITP
  • Heparin-induced thrombocytopenia
  • Drug-induced thrombocytopenia
  • DIC
  • Dilutional thrombocytopenia (massive transfusion)
  • TTP

Investigations

  • FBC + film; note timing relative to transfusion (5-12 days)
  • HPA (human platelet antigen) antibody testing — anti-HPA-1a (specialist)
  • Coagulation screen
  • Transfusion history and prior pregnancies

Management

  • Recognise severe thrombocytopenia 5-12 days post-transfusion
  • First line: IVIG (raises the count over days)
  • High-dose corticosteroids
  • Plasma exchange if refractory
  • AVOID random-donor platelet transfusion (ineffective, may worsen) — use HPA-1a-negative platelets ONLY for life-threatening bleeding
  • Tranexamic acid for mucosal bleeding
  • Flag for antigen-negative (HPA-1a-negative) blood components for any future transfusion
  • Haematology + transfusion medicine

Drugs & doses

IVIG (first-line)
Corticosteroids
HPA-1a-negative platelets (life-threatening bleeding only)
Tranexamic acid

Disposition

Admit; haematology and transfusion-medicine involvement.

Complications & pitfalls

  • Fatal haemorrhage (esp. intracranial)
  • Recurrence with future transfusion

Exam pearls

  • Severe thrombocytopenia ~1 week after transfusion in a parous woman = PTP
  • IVIG is first-line, NOT platelet transfusion
  • Random-donor platelets do not help — use HPA-1a-negative products
  • Flag for antigen-negative components for life

IVIG is first-line. Ordinary platelet transfusions are ineffective and may worsen PTP; reserve HPA-compatible platelets for life-threatening bleeding.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.